Express Scripts to seek discounts for Repatha Praluent
Express Scripts Holding Co. NASDAQESRX said its Pharmacy and Therapeutics P&T Committee will meet next month to evaluate whether to include PCSK9 inhibitors Repatha evolocumab and Praluent
View ArticleALNPCSsc Achieves Quarterly and Potentially BiAnnual Subcutaneous Dose...
Investigational FirstinClass PCSK9 Synthesis Inhibitor Achieves up to 83 Maximal and 64 Mean Maximum LDLC Lowering Comparable to Published Results with AntiPCSK9 Monoclonal Antibodies but with...
View ArticleAmgen Gets Nod for New Cholesterol Drug
Amgen has won US Food and Drug Administration FDA approval for Repatha the second medicine in a new class of biologics recently greenlighted by the agency and claimed to reduce cholesterol more...
View ArticleIntensive Statin Therapy and Coronary HighIntensity Plaques
Can the impact of intensive statin therapy be quantified with noncontrast imaging Journal of the American College of Cardiology
View ArticleTreatment with lifesaving drugs increases but still suboptimal in ischemic...
European Society of Cardiology Treatment with lifesaving medications has increased over the past 10 years in ischemic heart disease but levels are still suboptimal according to the first results of the...
View ArticleTreatment with lifesaving drugs increases but still suboptimal in ischaemic...
Treatment with lifesaving medications has increased over the past ten years in ischaemic heart disease but levels are still suboptimal according to the first results of the Chronic Ischaemic...
View ArticleStatin side effects linked to offtarget reaction in muscle mitochondria
Statins are a popular and easytoswallow option for people looking to lower their cholesterol. But for a quarter of patients statins come with muscle pain stiffness cramps or weakness without any clear...
View ArticleNew Analyses from the IMPROVEIT Study with VYTORINÂ ezetimibe and simvastatin
Further Analyses on the LongTerm Safety and Efficacy of VYTORINÂ from the IMPROVEIT Study Presented at the European Society of Cardiology ESC Meeting Merck NYSEMRK known as MSD in the United States and...
View ArticleBranded Acute Coronary Syndrome Therapies to Grab Market Share from Generic...
LONDON Sept. 2 2015 PRNewswire The acute coronary syndrome ACS therapeutics market consists of approximately 30 marketed branded drugs and hundreds of generics. While generic ACS drugs currently lead...
View ArticleCardioBrief No Diabetes Increase With Ezetimibe in IMPROVEIT
MedPage Today Trial subanalysis suggests no greater risk than with statin alone
View ArticleAmgen to sell Repatha in Europe at steep discount to US
Amgen's cholesterollowering antibody Repatha is being launched in Europe at well below the new drug's cost in the US raising the chance that American payers will seek hefty discounts on the...
View ArticleEarly Statin Use Following Recanalization Therapy for Stroke
Does early statin use following recanalization therapy improve the functional outcome of ischemic stroke BMC Neurology
View ArticleCHORI's Dr. Ronald Krauss receives $13.18 million NIH precision medicine grant
Children's Hospital & Research Center Oakland Children's Hospital Oakland Research Institute Senior Scientist Dr. Ronald Krauss has received a fiveyear $13.18 million grant from the NIH for...
View ArticleBoston Heart Reaches Milestone in Statin Intolerance Testing
Over 250000 Genotypes Performed to Help Identify Individual Risk of Statin Induced Myopathy; Data Confirm Research Findings of Risk Prevalence for Statin Side Effects. Boston Heart today announced that...
View ArticleICER publishes PCSK9 assessment
The Institute for Clinical and Economic Review ICER published an assessment of PCSK9 inhibitors Repatha evolocumab and Praluent
View ArticleNew cholesterollowering drugs are discussed by UB cardiologist and researcher
The new statin alternatives the class of drugs known as PCSK9 inhibitors which are just coming onto the market are a welcome addition for treating high cholesterol said Stanley F. Fernandez MD PhD...
View ArticleTreato Finds Demand Will be High for Heart Failure Drug Entresto
NEW YORK Sept. 9 2015 PRNewswire Consumer demand for Entresto a a potential blockbuster heart failure drug manufactured by Novartis will be high according to a data analysis released today by consumer...
View ArticleStudy Reconsiders Statin Therapy for Patients in Palliative Care Setting
Read more about Study Reconsiders Statin Therapy for Patients in Palliative Care SettingComments
View ArticleDiplomat to Dispense CholesterolLowering Drug REPATHA
FLINT Mich. Sept. 9 2015 PRNewswire Diplomat Pharmacy Inc. NYSE DPLO announced today that it will offer REPATHA&8482; evolocumab recently approved by the U.S. Food and Drug Administration to treat...
View Article